Lv2
128 积分 2023-09-08 加入
Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer
10天前
已完结
N-Nitrosamine Drug Substance Related Impurities (NDSRIs) – A proposal for the addition of subcategories to Carcinogenic Potency Categorisation Approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da
1个月前
已完结
On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes
1个月前
已完结
A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products
1个月前
已完结
Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines
1个月前
已完结
Safety assessment of drug impurities for patient safety: a comprehensive review
1个月前
已完结
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
1个月前
已完结
Regulatory Toxicology and Pharmacology New limits proposed for the management of non-mutagenic impurities
1个月前
已完结
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
7个月前
已完结
Strategy to Assess and Control Nitrosamine Formation in API during Storage: A Sitagliptin Case Study
7个月前
已完结
皖公网安备34019202002308
